Motesanib (Compound)

Synonyms:Motesanib, 453562-69-1, AMG 706, AMG-706, N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide, AMG706, N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide, Motesanib [USAN], N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, U1JK633AYI, CHEBI:51098, Motesanib (USAN), 453562-69-1 (free base), N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide, N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide, 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide, Motesanib [USAN:INN], UNII-U1JK633AYI, N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide, AMG706/ Motesanib, MOTESANIB [INN], MOTESANIB [MI], Motesanib (AMG-706), MOTESANIB [MART.], MOTESANIB [WHO-DD], SCHEMBL187470, CHEMBL572881, GTPL5660, BDBM24773, DTXSID10196488, EX-A487, cid_11667893, BCPP000407, HMS3244A09, HMS3244A10, HMS3244B09, HMS3265G19, HMS3265G20, HMS3265H19, HMS3265H20, BCP01982, AMG 706; AMG-706, MFCD10567689, NSC760843, NSC800801, s5793, AKOS005146333, N-(3,3-dimethylindolin-6-yl)-2-((pyridin-4-ylmethyl)amino)nicotinamide, BCP9000289, DB05575, EX-8571, NSC-760843, NSC-800801, SB14621, NCGC00263205-01, NCGC00263205-06, AC-32664, AS-16212, HY-10228, FT-0706483, A19395, D06678, J-522983, Q6917202, BRD-K99616396-316-01-2, N-(3,3-dimethylindolin-6-yl)-2-(4-pyridylmethylamino)nicotinamide, N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)-3-pyridinecarboxamide, N-(3,3-DIMETHYL-2,3-DIHYDRO-1H-INDOL-6-YL)-2-((PYRIDIN-4-YLMETHYL)AMINO)NICOTINAMIDE

Pubchem:PUBCHEM:11667893

Id:343f10da-ae15-546c-8f64-71b74fb976dc

Description:nan